Table S1. Strains used in this study

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Strain | Karyotype | Significance ofFitness loss# | Drug used for selection | Source |
| SC5314 | Euploid; Diploid |  |  | (Noble and Johnson 2005) |
| YJB T-3874 | Chr1x3 (AAB) | p<0.001 | Flucytosine | This study |
| YJB T-3875 | Chr1x3 (ABB) | p<0.001 | Flucytosine | This study |
| YJB T-3876 | Chr2x3 (AAB) | p<0.001 | Caspofungin | This study |
| YJB T-3877 | Chr2x3 (ABB) | p<0.001 | Caspofungin | This study |
| YJB T-3878 | Chr2x4 (AABB) | p<0.001 | Caspofungin | This study |
| YJB T-3879 | Chr3x3 (AAB) | p<0.001 | Brefeldin A | This study |
| YJB T-3880 | Chr3x3 (ABB) | p<0.05 | Brefeldin A | This study |
| YJB T-3881 | Chr4x3 (AAB) | p<0.05 | Ketoconazole | This study |
| YJB T-3882 | Chr4x3 (ABB) | p<0.05 | Ketoconazole | This study |
| YJB T-3883 | Chr5x1 (A) | p<0.001 | Caspofungin | This study |
| YJB T-3884 | Chr5x1 (B) | p<0.001 | Caspofungin | This study |
| YJB T-3885 | Chr5x3 (AAB) | p>0.05 | Aureobasidin A | This study |
| YJB T-3886 | Chr5x4 (AABB) | p<0.05 | Aureobasdin A | This study |
| YJB T-3887 | Chr6x3 (AAB) | p>0.05 | Myriosin | This study |
| YJB T-3888 | Chr6x3 (ABB) | p>0.05 | Myriosin | This study |
| YJB T-3889 | Chr7x3 (AAB) | p<0.001 | Fluconazole | This study |
| YJB T-3890 | Chr7x3 (ABB) | p<0.001 | Fluconazole | This study |
| YJB T-3891 | ChrRx3 (AAB) | p<0.05 | Fluconazole | This study |
| YJB T-3892 | ChrRx3 (ABB) | p<0.001 | Fluconazole | This study |

#P-values for fitness measuredby comparing the 24-h growth curves of the aneuploid and SC5314 parent growing in YPD at 37˚C.

**References**

Noble, S. M., and A. D. Johnson, 2005 Strains and strategies for large-scale gene deletion studies of the diploid human fungal pathogen Candida albicans. Eukaryot Cell 4**:** 298-309.